Abstract:The aggregation of amyloid-beta protein (A beta) into fibrillary deposits is implicated in Alzheimer's disease (AD), and inhibiting A beta aggregation and clearing A beta fibrils are considered as promising strategies to treat AD. It has been reported that resveratrol (RSV) and epigallocatechin-3-gallate (EGCG), two of the most extensively studied natural polyphenols, are able to inhibit A beta fibrillization and remodel the preformed fibrillary aggregates into amorphous, non-toxic species. However, the mechanisms by which RSV inhibits A beta(42) aggregation and disrupts A beta(42) protofibril, as well as the inhibitory/disruptive mechanistic similarities and differences between RSV and EGCG, remain mostly elusive. Herein, we performed extensive all-atom molecular dynamics (MD) simulations on A beta(42) dimers (the early aggregation state of A beta(42)) and protofibrils (the intermediate of A beta(42) fibril formation and elongation) in the absence/presence of RSV or EGCG molecules. Our simulations show that both RSV and EGCG can bind with A beta(42) monomers and inhibit the dimerization of A beta(42). The binding of RSV with A beta(42) peptide is mostly via pi-pi stacking interactions, while the binding of EGCG with A beta(42) is mainly through hydrophobic, pi-pi stacking, and hydrogen-bonding interactions. Moreover, both RSV and EGCG disrupt the beta-sheet structure and K28-A42 salt bridges, leading to a disruption of A beta(42) protofibril structure. RSV mainly binds with residues whose side-chains point inwards from the surface of the protofibril, while EGCG mostly binds with residues whose side-chains point outwards from the surface of the protofibril. Furthermore, RSV interacts with A beta(42) protofibrils mostly via pi-pi stacking interactions, while EGCG interacts with A beta(42) protofibrils mainly via hydrogen-bonding and hydrophobic interactions. For comparison, we also explore the effects of RSV/EGCG molecules on the aggregation inhibition and protofibril disruption of the Iowa mutant (D23N) A beta. Our findings may pave the way for the design of more effective drug candidates as well as the utilization of cocktail therapy using RSV and EGCG for the treatment of AD.

Influence of EGCG on Α‐synuclein (αs) Aggregation and Identification of Their Possible Binding Mode: A Computational Study Using Molecular Dynamics Simulation

Epigallocatechin Gallate Destabilizes Α-Synuclein Fibril by Disrupting the E46-K80 Salt-Bridge and Inter-protofibril Interface.

EGCG Attenuates Α-Synuclein Protofibril-Membrane Interactions and Disrupts the Protofibril

(-)-Epigallocatechin-3-gallate (EGCG) inhibits fibrillation, disaggregates amyloid fibrils of alpha-synuclein, and protects PC12 cells against alpha-synuclein-induced toxicity

Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson’s Disease

synuclein-induced toxicity

Molecular Insights into the Inhibition and Disaggregation Effects of EGCG on Aβ40 and Aβ42 Cofibrillation

The Inhibition Effect of Epigallocatechin-3-Gallate on the Co-Aggregation of Amyloid-β and Human Islet Amyloid Polypeptide Revealed by Replica Exchange Molecular Dynamics Simulations

Exploring the Influence of EGCG on the Β-Sheet-rich Oligomers of Human Islet Amyloid Polypeptide (hiapp1–37) and Identifying Its Possible Binding Sites from Molecular Dynamics Simulation

Green Tea Extracts EGCG and EGC Display Distinct Mechanisms in Disrupting Aβ42 Protofibril.

Understanding the mechanisms of green tea EGCG against amyloid β oligomer neurotoxicity through computational studies

Molecular insight into conformational transition of amyloid β-peptide 42 inhibited by (-)-epigallocatechin-3-gallate probed by molecular simulations.

Molecular mechanisms of resveratrol and EGCG in the inhibition of A<sub>42</sub> aggregation and disruption of A<sub>42</sub> protofibril: similarities and differences

Green tea extract EGCG plays a dual role in Aβ42 protofibril disruption and membrane protection: A molecular dynamic study.

Insights into Molecular Mechanisms of EGCG and Apigenin on Disrupting Amyloid-Beta Protofibrils Based on Molecular Dynamics Simulations

Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of Α-Synuclein.

Inhibition Mechanisms of (-)-epigallocatechin-3-gallate and Genistein on Amyloid-beta 42 Peptide of Alzheimer's Disease Via Molecular Simulations

Metal Chelator EGCG Attenuates Fe(III)‐induced Conformational Transition of Α‐synuclein and Protects AS‐PC12 Cells Against Fe(III)‐induced Death

Conformational Ensemble of Hiapp Dimer: Insight into the Molecular Mechanism by Which a Green Tea Extract Inhibits Hiapp Aggregation

Insights into the Cross-Amyloid Aggregation of Aβ40 and Its N-terminal Truncated Peptide Aβ11-40 Affected by Epigallocatechin Gallate

Thermodynamic Analysis of the Molecular Interactions between Amyloid β-Peptide 42 and (−)-Epigallocatechin-3-gallate